ClassID:

21556

A61K51/0472 - CPC Classification

Classification description:

Preparations containing radioactive substances for use in therapy or testing characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus; Organic compounds; Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol

Recent Application in this class:
#1
20240399001
2024-12-05

RADIOTRACERS AND THERAPEUTICS BINDING TO FIBROBLAST ACTIVATION PROTEIN (FAP)

#2
20240350679
2024-10-24

RADIOLABELING AND FORMULATION FOR SCALE UP OF 64Cu-DOTATATE

#3
20240226346
2024-07-11

LOADING OF HUMAN CAR T-CELLS WITH SUPERPARAMAGNETIC IRON-BASED PARTICLES FOR MAGNETIC TARGETING

#4
20240024521
2024-01-25

LOADING OF HUMAN CAR T-CELLS WITH SUPERPARAMAGNETIC IRON-BASED PARTICLES FOR MAGNETIC TARGETING

#5
20230348405
2023-11-02

PSMA-TARGETING COMPOUNDS AND USES THEREOF

#6
20220259161
2022-08-18

PSMA-targeting compounds and uses thereof

#7
20220125957
2022-04-28

METHODS OF TREATING CANCER

#8
20220080059
2022-03-17

Radiolabeling and formulation for scale up of Cu-DOTATATE

#9
20220048872
2022-02-17

PSMA targeted fluorescent agents for image guided surgery

#10
20210228748
2021-07-29

IN VIVO STABLE HG-197(M) COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF IN NUCLEAR MEDICAL DIAGNOSTICS AND ENDORADIONUCLIDE THERAPY (THERANOSTICS)

#11
20200369698
2020-11-26

Preparation of metal-pyridine derivative complexes for use in medical imaging

#12
20200216402
2020-07-09

PSMA targeted fluorescent agents for image guided surgery

#13
20200138985
2020-05-07

KIT FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE

#14
20200109124
2020-04-09

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

#15
20180282333
2018-10-04

2,11-diaza-[3.3](2,6)pyridinophane compounds and their application as ligands of essential metal ion based MRI contrast agents and 52MN based PET contrast agents

#16
20180085478
2018-03-29

Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents

#17
20180036439
2018-02-08

COUPLED IDENTIFICATION AND TREATMENT OF CANCER

#18
20180009767
2018-01-11

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

#19
20170283384
2017-10-05

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

#20
20160256579
2016-09-08

METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE

#21
20160199500
2016-07-14

COMPOSITIONS COMPRISING VITAMIN B12 AND INTRINSIC FACTOR AND METHODS OF USE THEREOF

#22
20160052894
2016-02-25

Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using

#23
20160022844
2016-01-28

Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications

#24
20150246144
2015-09-03

Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents

#25
20150104387
2015-04-16

PSMA-targeting compounds and uses thereof

#26
20150037253
2015-02-05

METAL COMPLEXES AS IMAGING AGENTS

#27
20140234216
2014-08-21

Folate conjugates of albumin-binding entities

#28
20140228551
2014-08-14

Compositions, methods of synthesis and use of carbohydrate targeted agents

#29
20140178298
2014-06-26

Methods for tumor diagnosis and therapy

#30
20140093451
2014-04-03

Coupled identification and treatment of cancer

#31
20130323172
2013-12-05

Molecular probes for multimodality imaging of anionic membrane surfaces

#32
20130323168
2013-12-05

Agents and methods for visualizing analytes

#33
20130287687
2013-10-31

COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT

#34
20120213701
2012-08-23

Methods for tumor diagnosis and therapy

#35
20120009121
2012-01-12

PSMA-targeting compounds and uses thereof

#36
20110318265
2011-12-29

Coupled identification and treatment of cancer

#37
20110305636
2011-12-15

Compounds, compositions, methods of synthesis, and methods of treatment

#38
20110064657
2011-03-17

Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents

#39
20090285755
2009-11-19

Compounds for tumor diagnosis and therapy